The new year is off to a busy start with several recent financing and funding announcements coming from across the biotechnology sector, highlighting a continued interest in late-stage clinical assets and platform-driven approaches, such as genetic medicine, immunology, and chronic respiratory diseases.

Recent finance and funding activity includes Medipost Inc. with a $140 million funding to accelerate late-stage clinical development, AirNexis Therapeutics’ $200 million Series A launch to advance a Phase II dual PDE3/4 inhibitor for COPD, SonoThera’s $125 million Series B to move multiple genetic medicine programs toward first-in-human studies, and 32 Biosciences’ $40 million Series A to support development of first-in-class gastrointestinal mucosal immune therapeutics.

Medipost Inc.

Medipost Inc. announced a $140 million financing round to support late-stage clinical development of its cell-based therapeutic programs.¹ The funding is expected to accelerate both global clinical trials and regulatory preparation for lead candidates targeting inflammatory and degenerative conditions.

According to the company, the raised capital is set to advance pivotal studies while also strengthening its manufacturing and development capabilities, while its programs approach potential commercialization.¹

“The funding from Korea’s top growth equity funds fuels Medipost’s global expansion as we prepare to advance into Phase III clinical evaluation in the U.S., with trial initiation anticipated in early 2026,” said Edward Ahn, PhD, chief executive officer of Medipost Inc. “It allows us to move into late-stage development while continuing to build the clinical, operational and manufacturing foundation needed to bring scalable, off-the-shelf regenerative therapies closer to patients.”

AirNexis Therapeutics

AirNexis Therapeutics has launched with a $200 million Series A financing to advance AN01, a dual PDE3/4 inhibitor in Phase II development for chronic obstructive pulmonary disease (COPD).²

The company is positioning AN01 as a differentiated oral therapy aimed at addressing both inflammation and bronchoconstriction, two central drivers of COPD pathology. AirNexis plans to use the proceeds from the financing to support Phase II clinical studies and broader pipeline development in respiratory disease.²

The Series A was led by Frazier Life Sciences, and included participation from OrbiMed, SR One, Life Sciences at Goldman Sachs Alternatives, Longitude Capital and Enavate Sciences among others.²

SonoThera

SonoThera announced it is set to launch a $125 million Series B at the 44^th J.P. Morgan Healthcare Conference to advance several genetic medicine programs toward first-in-human studies.³ Currently, SonoThera is developing non-viral delivery technologies designed to enable targeted genetic therapies across a range of indications.

The funding is expected to support preclinical-to-clinical transition activities, including IND-enabling studies and manufacturing scale-up.³

“As we accelerate our pipeline, we continue to demonstrate UMD’s ability to safely and efficiently deliver oversized genetic payloads, unlocking some of the largest opportunities in genetic medicine,” said Ken Greenberg, PhD, CEO of SonoThera. “Our Series B will advance multiple clinical programs and support a steady cadence of data through 2028.”

32 Biosciences

32 Biosciences revealed its plan to launch a $40 million Series A at this year’s J.P Morgan Healthcare conference, to advance CS-0003, a first-in-class Mucosal-Immune Modulator (MIM) designed to buffer the GI tract by coating and protecting the mucosal barrier, suppressing bacterial virulence, and modulating the mucosal-immune system.⁴

The company’s platform is focused on restoring immune balance at the GI mucosal surface, with initial programs targeting inflammatory and immune-mediated gastrointestinal diseases.

According to 32 Bioscience, the financing is expected to help progress lead candidates through early clinical development and to expand the company’s research pipeline.

“Launching our Series A at JPM is a key step as we advance CS-0003 into the clinic and build our GB discovery platform,” said Peter Farmakis, chairman & chief executive officer of 32 Biosciences. “We’re restoring and protecting the gut mucosal-immune system—an overlooked but central driver of surgical outcomes and chronic disease, with the goal of meaningfully improving outcomes for patients facing serious GI disease.”

Sources

1. Medipost Inc. Announces $140 Million in Funding to Accelerate Late-Stage Clinical Development Medipost Inc January 9, 2026 https://www.businesswire.com/news/home/20260109323917/en/MEDIPOST-Inc.-Announces-%24140-Million-in-Funding-to-Accelerate-Late-Stage-Clinical-Development
2. AirNexis Therapeutics Launches with $200M Series A to Advance Phase 2 Dual PDE3/4 Inhibitor AN01 for Chronic Obstructive Pulmonary Disease (COPD) AirNexis Therapeutics January 9, 2026 https://www.businesswire.com/news/home/20260109716906/en/AirNexis-Therapeutics-Launches-with-%24200M-Series-A-to-Advance-Phase-2-Dual-PDE34-Inhibitor-AN01-for-Chronic-Obstructive-Pulmonary-Disease-COPD
3. SonoThera Launches $125M Series B at 44th J.P. Morgan Healthcare Conference to Advance Multiple Genetic Medicine Programs Toward First-in-Human Studies SonoThera January 8, 2026 https://www.businesswire.com/news/home/20260108648924/en/SonoThera-Launches-%24125M-Series-B-at-44th-J.P.-Morgan-Healthcare-Conference-to-Advance-Multiple-Genetic-Medicine-Programs-Toward-First-in-Human-Studies
4. 32 Biosciences to Launch $40 Million Series A at J.P. Morgan to Advance First-in-Class GI Mucosal-Immune Therapeutics 32 Biosciences January 8, 2026 https://www.businesswire.com/news/home/20260108625100/en/32-Biosciences-to-Launch-%2440-Million-Series-A-at-J.P.-Morgan-to-Advance-First-in-Class-GI-Mucosal-Immune-Therapeutics